Company News

Aug 17, 2010

MabVax Therapeutics Receives Small Business Innovation Research Program Award From The National Cancer Institute

San Diego, CA, August 17, 2010 -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Busines Read More...

Filed Under: Company News

Aug 09, 2010

Lentigen Awarded Phase II SBIR Grant for Clinical Development of TCR

Gaithersburg , MD, August 9, 2010 – Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a N Read More...

Filed Under: Company News

May 18, 2010

Lentigen Awarded Phase I STTR Grant for Hunter Syndrome

GAITHERSBURG, Md., May 18 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business technology transfer (STTR) g Read More...

Filed Under: Company News

Apr 22, 2010

Lentigen and IAVI to Collaborate on Design of Novel AIDS Vaccine Candidate

The International AIDS Vaccine Initiative (IAVI) and Lentigen today announced a collaboration to design a preventive AIDS vaccine based on Lentigen's technology. The candidate AIDS vaccine will be devised to safely mimic biological aspects of HIV infection and tested first in pre-clinical studie Read More...

Filed Under: Company News

Mar 17, 2010

The Flexstent Femoropopliteal Self-Expanding Stent

When lifestyle changes and/or medication alone are not an effective treatment for peripheral artery disease (PAD), endovascular or surgical procedures become an option. Endovascular devices and surgical treatment for PAD represent a major challenge for physicians treating superfi Read More...

Filed Under: Company News

Sep 29, 2009

Flexible Stenting Solutions, Inc. Receives Conditional IDE Approval For FlexStent(R) Femoropopliteal Self Expanding Stent System

Flexible Stenting Solutions Inc. ("FSS"), a leading developer of next generation peripheral arterial and biliary stents, announced that it has received Conditional Investigational Device Exemption (IDE) approval for its FlexStent� Femoropopliteal Self Expanding Stent System. With this approval, FSS Read More...

Filed Under: Company News

Sep 17, 2009

Flexible Stenting Solutions, Inc. Receives 510(k) Clearance for FlexStent Biliary Self Expanding Stent System

EATONTOWN, N.J.--(Business Wire)--Flexible Stenting Solutions Inc. ("FSS"), a leading developer of next generationperipheral arterial and biliary stents, received 510(k) clearance for the FlexStent� Biliary Self Expanding Stent System. The FlexStent� Biliary Self Expanding Stent System is indica Read More...

Filed Under: Company News

Aug 24, 2009

Flexible Stenting Solutions Inc. and Micrus Endovascular Sign Licensing and Development Agreement for Flow Diversion Technology

SAN JOSE, Calif.--(BUSINESS WIRE)--Micrus Endovascular Corporation (Nasdaq: MEND - News) and privately held Flexible Stenting Solutions Inc. of Eatontown, N.J., today announced the signing of an exclusive agreement to jointly develop a flow diversion technology for neurovascular indicati Read More...

Filed Under: Company News

Jun 25, 2009

Lentigen Collaborator Case Western Reserve University Receives $5M From Third Frontier Commission for the Center for Stem Cell & Regenerative Medicine

CLEVELAND, June 25 /PRNewswire-USNewswire/ -- The Center for Stem Cell & Regenerative Medicine (CSCRM), comprised of Case Western Reserve University (CWRU), Cleveland Clinic (CC), University Hospitals (UH), and Athersys, Inc. has received $5 million from Ohio's Third Frontier Commission Read More...

Filed Under: Company News

Feb 04, 2009

Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement

GAITHERSBURG, Md. and ATLANTA, Feb 4 -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, and Expression Therapeutics, a biotechnology company specializing in factor VIII-based therapeutics, today announced Read More...

Filed Under: Company News

53 results:

1234...6>>